Foods Atazanavir

Therapy-naive patients 400 mg (two 200 mg capsules) once daily taken with food. Therapy-experienced patients Atazanavir 300 mg (two 150 mg capsules) once daily... 

Didanosine-buffered formulations - Give atazanavir (with food) 2 hours before or 1 hour after didanosine. 

Ritonavir- It is recommended that atazanavir 300 mg once daily be given with ritonavir 100 mg once daily with food. 

Tenofovir disoproxil fumarate - It is recommended that atazanavir 300 mg be given with ritonavir 100 mg and tenofovir 300 mg (all as a single daily dose with food). Atazanavir without ritonavir should not be coadministered with tenofovir. 

Effect of food - Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. 

HIV-1 infection concurrent therapy withe favirenz) PO 300 mg atazanavir, 100 mg ritonavir, and 600 mg efavirenzas a single daily dose with food. 

Atazanavir PI2 400 mg daily or 300 mg daily with ritonavir 100 daily. Adjust dose in hepatic insufficiency Take with food. Separate dosing from ddl or antacids by 1 h. Separate dosing from cimetidine and other acid-reducing agents by 12 h Nausea, vomiting, diarrhea, abdominal pain, headache, peripheral neuropathy, skin rash, indirect hyperbilirubinemia, prolonged PR and/or QTC interval See footnote 4 for contraindicated medications. Also avoid indinavir, irinotecan, and omeprazole. Avoid in severe hepatic insufficiency... 

Tenofovir NRTI1 300 mg qd3 Take with food. Nausea, diarrhea, vomiting, flatulence, headache, renal insufficiency Avoid concurrent atazanavir, probenecid, didanosine... 

Atazanavir Atazanavir is a peptide protease inhibitor that is active against both HlV-1 and HlV-2. Absorption is increased by food and it is recommended that the drug be administered with a meal. Absorption may be pH dependent, because proton pump inhibitors substantially reduce drug concentration after oral dosing. Like indinavir, atazanavir frequently causes unconjugated hyperbilirubinemia. The drug may be less likely than other HIV protease inhibitors to cause lipodystrophy. 

Atazanavir 11 (Figure 16.4A) is an acyclic aza-peptidomimetic, a potent HIV protease inhibitor [43,44] approved recently by the U.S. Food and Drug Adminstration for treatment of autoimmune diseases (e.g., AIDS). An enzymatic process has been developed for the preparation of (lS,2/ )-[3-chloro-2-hydroxy-l-(phenylmethyl)pro-pyljcarbamic acid, 1,1-dimethylethyl ester 13 (Figure 16.4B), akey chiral intermediate... 

Atazanam. The manufacturer of atazanavir found that buffered didanosine markedly decreased atazanavir plasma levels, with little change in didanosine levels, and they recommend that administration should be separated. " Conversely, although enteric-coated didanosine did not alter atazanavir levels, simultaneous administration with food reduced didanosine levels, and therefore administration should be separated. Note that didanosine , (p.797), is preferably taken on an empty stomach, whereas atazanavir , (p.818), should be taken with food. 

Food increases the bioavailability of atazanavir, darunavir, lopinavir/ritonavir soft capsules and solution, nelfinavir, saquinavir (all formulations) and tipranavir, but decreases that of indinavir. Food only minimally affects the bioavailability of amprenavir, fosamprenavir, lopinavir/ritonavir tablets and ritonavir. Mixing ritonavir with enteral feeds does not affect the pharmacokinetics of ritonavir. 

Atazanavir. The manufacturers of atazanavir note that administration with a light or high-fat meal decreased the wide variation in plasma levels. They recommend that atazanavir should be taken with food to enhance bioavailability and minimise variability. - ... 

Atazanavir 78 (Figure 11.22) is an acyclic aza-peptidomimetic, a potent HIV protease inhibitor [138-140] approved by the Food and Drug Administration for the treatment of Acquired Immunodeficiency Syndrome (AIDS). An... 

---